Introducing the Digital RESI January Agenda

3 Dec

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireIntegral to Life Science Nation (LSN)’s Inaugural LSN Healthtech Partnering Week are the panel discussions featuring industry leaders and their insight into the early-stage fundraising ecosystem. The upcoming 3-day digital Redefining Early Stage Investments (RESI) Conference, January 11-13, kicks off Healthtech Partnering Week, and will feature 10 panels discussing various aspects of life science and healthcare fundraising.

All RESI panels are held live during the conference and feature active investors as panelists. From sector-focused panels like Early Stage Therapeutics and Medical Devices to panels focused on different types of investors like Family Offices and Corporate Venture Capital, there are relevant topics for all fundraising entrepreneurs and fellow investors who are seeking to gain valuable insights as they continue to make a mark in the life science industry.

We will also feature the Innovator’s Pitch Challenge (IPC) – virtual pitch sessions in which participating companies receive a dedicated webpage on our agenda and the opportunity to engage in a live Q&A session with investors and strategic partners interested in their products and services.

IPC companies pitch to a panel of judges featuring active investors and prominent industry experts and stay for a live Q&A. These sessions provide valuable insights and feedback to help companies improve on their capabilities.

If you are a fundraising CEO, you do not want to miss out on this opportunity. You can apply for free below!

Example of a Company’s Landing Page

We will also have a variety of workshops featuring topics relevant to the early-stage life science ecosystem. Though we cannot gather at San Francisco, as we have done for many consecutive years, we hope you can join us for RESI at Healthtech Partnering Week! RESI super early bird rates apply until December 4, so sign up today and save!

 

A Conversation with Helena Cowley, CEO of Oxidien Pharmaceuticals

3 Dec

By Rory McCann, Marketing Manager & Conference Producer, LSN

Helena Cowley, MS, MBA is CEO of Oxidien Pharmaceuticals, a therapeutics company mitigating kidney stone disease by using enzyme compounds to treat secondary hyperoxaluria. We recorded our chat about the early days of Oxidien and how they’ve navigated the fundraising landscape. We discuss conferences, networking, and tools to give early-stage companies an edge when meeting with strategic partners.

To learn more about RESI and Life Science Nation’s premier partnering events this September, visit www.resipartneringweek.com. Digital RESI Partnering Week September super early bird rates apply until July 23, so sign up today to start meeting with investors and strategic partners to jumpstart your 2021 fundraising goals!

 

Hot Investor Mandate: Corporate Venture Arm of Large Asian Manufacturing Company Invests in Therapeutics, Medical Devices, Diagnostics

3 Dec

A corporate venture/life science investment arm of a global life science, and medical equipment manufacturer invests from an evergreen fund and prefers to invest at company formation/seed stage, but no later than Series A. Typical investments range from USD1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these sectors.

The firm prefers to invest in teams with a strong track record but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of the parent company to help companies with regulatory affairs, market access, and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Canada VC Firm Invests Up to $5M in Early-Stage Therapeutics, Diagnostics, Healthcare Platforms With Focus in North America

3 Dec

A Canada-based venture capital firm focuses on investments in three main sectors: Biopharmaceutical, Healthcare Platform & Services, and Technology. The firm provides initial investments at USD 3-5 million, and it will also reserve a further amount for follow-on financing and supports the startups in strategic partnerships. The firm is interested in pre-clinical to clinical-stage biotech companies. The firm invests primarily in North America but also opens to invest in Europe or China.

The firm is looking for new opportunities in the life science space, including therapeutics, diagnostics, and healthcare platforms. The firm’s investments to date have included companies developing in cell therapy, oncology, neuroscience, and drug-discovery platform. The firm is opportunistic in terms of sector, subsectors, and indications. The firm will also consider orphan drugs. Within medical devices and digital health, the firm will only consider companies that already have a USD 10 million minimum revenue. The firm will only co-invest and will prefer to co-invest with well-known lead investors.

The firm does not have specific requirements on companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe Investment Firm Seeks Medical Devices & Diagnostics Opportunities in USA, Europe, and Israel

3 Dec

A venture capital firm in Western Europe seeks to make 4-5 investments over the next 6 to 12 months. The firm could lead any investment up to €15M but will also look for syndicate participation in bigger rounds. Allocations are in the form of equity. Allocations are typically made at the venture stage of development but are open to consider Seed through IPO rounds. The firm focuses on companies based in Europe, but also considers companies in Israel and USA.

The firm will look at a broad spectrum of products and services within the life science space. While the firm has traditionally not considered therapeutics, the firm is now open to making investments in this space. The firm is most interested in medical devices and diagnostics including in-vitro diagnostics, and also looks into digital health. They will look at any stage of development within those categories and long as the product or service shows substantial market potential and have proof of concept.

The firm is willing to work with all types of management teams as long as entrepreneurs/founders have a solid knowledge in the industry. A board seat is required for all investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Evergreen Venture Fund Interested in Therapeutics Companies Across All Indications, Open to Global Opportunities

3 Dec

An evergreen venture fund based in the USA is a flexible investor; the firm’s initial allocations vary depending on the company’s developmental stage, from $150,000 to several million dollars. The firm is open to being a lead investor, and will consider opportunities globally. The firm is open to investing in both privately held companies and publicly traded companies.

The firm invests in the therapeutics sector. The firm only invests in companies with assets that are at the clinical phase of development, and which are based on solidly vetted science. The firm is agnostic in therapeutic indications and will consider opportunities in any area of medicine.

The firm likes to invest as part of a syndicate in science at a US or OUS company that will create a value inflection from a well executed study. The firm has a flexible approach to management teams and may be a more hands-on investor if the management team has limited business experience. The firm prefers to invest in companies that already have an exit plan in mind.  The firm requires a high level of transparency from portfolio companies, and guides portfolio companies in planning studies that will create real value inflection points for the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Why Failure is Falling Upwards ​​​​​​​– Learn from Entac Medical Founder, Buddy Lyons, and Find Out How RESI became Part of the Success Story

19 Nov

By Rory McCann, Marketing Manager & Conference Producer, LSN

Failure is an unwelcome companion on the entrepreneurial journey, and one most founders avoid at all costs. To Buddy Lyons, Founder and CEO of Entac Medical, failure (or the threat of it) can play an integral role in a company’s development, growth, and eventual success. Entac Medical is developing non-invasive devices for diagnosis, particularly to surgical patients. Hear their story and listen to my conversation with Buddy about the earliest days of Entac, and what got them through the most trying times.

← Older Entries
Newer Entries →